company-logo

Nxera Pharma Co., Ltd. develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its product portfolio products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair and Breezhaler for the treatment of asthma; ORAVI, a novel formulation for the treatment of oropharyngeal candidiasis; and PIVLAZ for the treatment of cerebral vasospasm indications. The company's development products pipeline consists of HTL0039732 for immuno-oncology indications; HTL0048149 for schizophrenia disorders; Daridorexant for the treatment of insomnia; HTL0016878 for schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; PF-07258669 for anorexia; PF-06954522 for metabolic diseases; NBI-1117569 for neurology diseases; and NBI-1117570 for central nervous system (CNS) disorders. It is also involved in the development of GPR35 agonist, for inflammatory bowel disease/GI disorders, which is in preclinical stage; and other discovery and preclinical stage drugs. Nxera Pharma Co., Ltd. has a strategic collaboration with AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily. Nxera Pharma Co., Ltd. was incorporated in 1990 and is headquartered in Tokyo, Japan.

Nxera Pharma Dividend Announcement

Nxera Pharma announced a annually dividend of ¥10.00 per ordinary share which will be made payable on . Ex dividend date: 2015-03-27
Nxera Pharma's trailing twelve-month (TTM) dividend yield is -%

Nxera Pharma Dividend History

Ex-Div dateDividend amountDividend typePay date
2015-03-27¥10.00annually

Nxera Pharma Dividend per year

Nxera Pharma Dividend Yield

Nxera Pharma current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Nxera Pharma stock? Use our calculator to estimate your expected dividend yield:

Nxera Pharma Financial Ratios

P/E ratio-29.87
PEG ratio-23.22
P/B ratio1.64
ROE-5.51%
Payout ratio0.00%
Current ratio4.01
Quick ratio3.90
Cash Ratio3.27

Nxera Pharma Dividend FAQ

Does Nxera Pharma stock pay dividends?
Nxera Pharma does not currently pay dividends to its shareholders.
Has Nxera Pharma ever paid a dividend?
No, Nxera Pharma has no a history of paying dividends to its shareholders. Nxera Pharma is not known for its dividend payments.
Why doesn't Nxera Pharma pay dividends?
There are several potential reasons why Nxera Pharma would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Nxera Pharma ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Nxera Pharma has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Nxera Pharma a dividend aristocrat?
Nxera Pharma is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Nxera Pharma a dividend king?
Nxera Pharma is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Nxera Pharma a dividend stock?
No, Nxera Pharma is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Nxera Pharma stocks?
To buy Nxera Pharma you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Nxera Pharma stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.